secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUNIC, INC. (IMUX)
CIK:        0001280776
Form:       8-K
Filed at:   2024-02-22T23:59:59+00:00
Accession:  0001193805-24-000257
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunic reports FY2023 net loss of $93.6M; raises $80M in Jan 2024 private placement
--------------------------------------------------------------------------------

- Net loss for FY2023: $93.6M ($2.11 per share) vs $120.4M ($3.78 per share) in FY2022.
- Cash as of Dec 31, 2023: $46.7M; extended to Q3 2025 after $80M Jan 2024 private placement tranche.
- Positive interim phase 2 CALLIPER data: vidofludimus calcium reduced NfL in PMS; top-line data expected April 2025.
- Phase 3 ENSURE interim futility analysis expected late 2024; first read-out Q2 2026.
- New US patents granted for vidofludimus calcium dosing regimens, providing protection into 2041.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1280776/000119380524000257/0001193805-24-000257-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1280776/000119380524000257/e619294_8k-immunic.htm
  HTML page:      https://secwatch.observer/filing/0001193805-24-000257

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer